ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO898

DNA Methylation of Klotho Promotor Gene Is Associated with Cardiovascular Disease and Malnutrition in Patients Under Hemodialysis

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Honda, Hirokazu, Showa University Koto Toyosu Hospital, Tokyo, Japan
  • Kobayashi, Yasuna, Niigata University of Pharmaceutical Sciences, Niigata, Japan
  • Aruga, Seiki, Monnaka Jin Clinic, Tokyo, Japan
  • Uetake, Daijiro, Toyosu Jin Clinic, Tokyo, Japan
  • Shibata, Takanori, Showa University School of Medicine, Tokyo, Japan
Background

Cardiovascular disease (CVD) and protein-energy wasting are common in patients under hemodialysis (HD). While multiple factors are associated with those comorbidities, we hypothesized that gene silencing, including alteration of epigenome might influence the comorbidities in HD patients. Thus, the aim of this ongoing study is to assess the prevalence of epigenetic modifications of Klotho, aging-related genes, and its association of comorbidities.

Methods

Whole blood samples were drawn in 131 prevalent HD patients and genomic DNA were purified from white blood cells. Epigenetic modifications of Klotho promotor gene were defined by methylation of CpG sites. Extracted DNA were modified by bisulfate treatment and then the methylated sequences were selectively amplified by methylation-specific PCR. The products were visualized by agarose gels and were quantified. Patient characteristics, complication and baseline laboratory data were recorded.

Results

Epigenetic analysis had performed in one hundred and twenty-five patients of 131. Of 125, 48 patients showed the DNA methylation of Klotho promotor gene. Patients with Klotho gene methylation had high prevalence rate of CVD such as acute coronary syndrome and myocardial infarction, and low levels of serum albumin and creatinine and geriatric nutritional risk index compared with those without Klotho gene methylation.

Conclusion

Epigenetic modifications of Klotho promotor gene may be associated with CVD complication and malnutrition in patients under HD.